Molecular imaging of the dopamine transporter

Journal of Nuclear Medicine

Volumn 51, Issue 9, 2010, Pages 1331-1334

  Varrone, Andrea ^a   Halldin, Christer ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

DAT availability; Parkinson; Substantia nigra

Indexed keywords

2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)TROPANE IODINE 123; DOPAMINE TRANSPORTER; N 3 FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE IODINE 123; RADIOLIGAND; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DOPAMINE;

ALZHEIMER DISEASE; ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; COGNITION; ESSENTIAL TREMOR; EUROPE; FRONTOTEMPORAL DEMENTIA; HUMAN; HUNTINGTON CHOREA; LEWY BODY; LOCOMOTION; MOLECULAR IMAGING; NONHUMAN; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; REWARD; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; METABOLISM; METHODOLOGY; PARKINSON DISEASE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BIOLOGICAL MARKERS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MOLECULAR IMAGING; PARKINSON DISEASE;

EID: 77957100232     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.065656     Document Type: Review

References (20)

1. Bannon MJ. The dopamine transporter: role in neurotoxicity and human disease. Toxicol Appl Pharmacol. 2005;204:355-360. (Pubitemid 40545237)
2. 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2009;37:443-450.
3. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/ hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry. 2005;57:229-238. (Pubitemid 40187366)
4. Erixon-Lindroth N, Farde L, Wahlin TB, Sovago J, Halldin C, Backman L. The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res. 2005;138:1-12. (Pubitemid 40228957)
5. 11C]LBT- 999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET. Synapse. 2007;61:17-23.
6. 18F]FE-PE2I, a new dopamine transporter PET radioligand. Synapse. 2009;63:871-880.
7. 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a doubleblind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007;48:359-366.
8. 123I-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord. 2004;19:1175-1182.
9. 123I]beta-CIT SPECT and prefrontal cognitive functions in Parkinson's disease. J Neural Transm. 2000;107:303-319.
10. 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305-313.
11. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol. 2004;56:173-181. (Pubitemid 39037913)
12. Stiasny-Kolster K, Doerr Y, Moller JC, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain. 2005;128:126-137.
13. Marek K, Jennings D. Can we image premotor Parkinson disease? Neurology. 2009;72(7, suppl)S21-S26.
14. Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson's disease follows a single exponential rather than linear decline. J Nucl Med. 2004;45:1694-1697. (Pubitemid 47618477)
15. Fahn S. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol. 2005;252(suppl 4):IV37-IV42.
16. Pogarell O, Koch W, Gildehaus FJ, et al. Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging. 2006;33:407-411.
17. Hesse S, Strecker K, Winkler D, et al. Effects of subthalamic nucleus stimulation on striatal dopaminergic transmission in patients with Parkinson's disease within one-year follow-up. J Neurol. 2008;255:1059-1066.
18. Spencer TJ, Biederman J, Madras BK, et al. Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using Altropane. Biol Psychiatry. 2007;62:1059-1061. (Pubitemid 47562362)
19. Hesse S, Ballaschke O, Barthel H, Sabri O. Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. Psychiatry Res. 2009;171:120-128.
20. Volkow ND, Wang GJ, Kollins SH, et al. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA. 2009;302:1084-1091.